These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

111 related articles for article (PubMed ID: 33244802)

  • 1. Parotid gland stem cells: Mini yet mighty.
    Sari SY; Yilmaz MT; Elmali A; Yedekci FY; Yuce D; Ozyigit G; Cengiz M; Yazici G
    Head Neck; 2021 Apr; 43(4):1122-1127. PubMed ID: 33244802
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Volumetric changes of the parotid gland during IMRT based on mid-treatment imaging: implications for parotid stem cell sparing strategies in head and neck cancer.
    Gjini M; Ahmed S; Kalnicki S; Tomé WA; Garg MK; Kabarriti R; Brodin NP
    Acta Oncol; 2022 Sep; 61(9):1069-1074. PubMed ID: 35978529
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Early Prediction of Acute Xerostomia During Radiation Therapy for Head and Neck Cancer Based on Texture Analysis of Daily CT.
    Wu H; Chen X; Yang X; Tao Y; Xia Y; Deng X; Zheng C; Robbins J; Schultz C; Li XA
    Int J Radiat Oncol Biol Phys; 2018 Nov; 102(4):1308-1318. PubMed ID: 29891201
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Can dose reduction to one parotid gland prevent xerostomia?--A feasibility study for locally advanced head and neck cancer patients treated with intensity-modulated radiotherapy.
    Anand AK; Jain J; Negi PS; Chaudhoory AR; Sinha SN; Choudhury PS; Kumar R; Munjal RK
    Clin Oncol (R Coll Radiol); 2006 Aug; 18(6):497-504. PubMed ID: 16909975
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Early Changes in Serial CBCT-Measured Parotid Gland Biomarkers Predict Chronic Xerostomia After Head and Neck Radiation Therapy.
    Rosen BS; Hawkins PG; Polan DF; Balter JM; Brock KK; Kamp JD; Lockhart CM; Eisbruch A; Mierzwa ML; Ten Haken RK; El Naqa I
    Int J Radiat Oncol Biol Phys; 2018 Nov; 102(4):1319-1329. PubMed ID: 30003997
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Parotid gland mean dose as a xerostomia predictor in low-dose domains.
    Gabryś HS; Buettner F; Sterzing F; Hauswald H; Bangert M
    Acta Oncol; 2017 Sep; 56(9):1197-1203. PubMed ID: 28502238
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Parotid gland radiation dose-xerostomia relationships based on actual delivered dose for nasopharyngeal carcinoma.
    Lou J; Huang P; Ma C; Zheng Y; Chen J; Liang Y; Li H; Yin Y; Liu D; Yu G; Li D
    J Appl Clin Med Phys; 2018 May; 19(3):251-260. PubMed ID: 29664218
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Texture analysis as a predictor of radiation-induced xerostomia in head and neck patients undergoing IMRT.
    Nardone V; Tini P; Nioche C; Mazzei MA; Carfagno T; Battaglia G; Pastina P; Grassi R; Sebaste L; Pirtoli L
    Radiol Med; 2018 Jun; 123(6):415-423. PubMed ID: 29368244
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prediction of Radiation-Induced Parotid Gland-Related Xerostomia in Patients With Head and Neck Cancer: Regeneration-Weighted Dose.
    van Rijn-Dekker MI; van Luijk P; Schuit E; van der Schaaf A; Langendijk JA; Steenbakkers RJHM
    Int J Radiat Oncol Biol Phys; 2023 Nov; 117(3):750-762. PubMed ID: 37150262
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Dosimetric predictors of xerostomia for head-and-neck cancer patients treated with the smart (simultaneous modulated accelerated radiation therapy) boost technique.
    Amosson CM; Teh BS; Van TJ; Uy N; Huang E; Mai WY; Frolov A; Woo SY; Chiu JK; Carpenter LS; Lu HH; Grant WH; Butler EB
    Int J Radiat Oncol Biol Phys; 2003 May; 56(1):136-44. PubMed ID: 12694832
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A novel dose constraint to reduce xerostomia in head-and-neck cancer patients treated with intensity-modulated radiotherapy.
    Strigari L; Benassi M; Arcangeli G; Bruzzaniti V; Giovinazzo G; Marucci L
    Int J Radiat Oncol Biol Phys; 2010 May; 77(1):269-76. PubMed ID: 20100642
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Scintigraphic assessment of salivary function after intensity-modulated radiotherapy for head and neck cancer: correlations with parotid dose and quality of life.
    Chen WC; Lai CH; Lee TF; Hung CH; Liu KC; Tsai MF; Wang WH; Chen H; Fang FM; Chen MF
    Oral Oncol; 2013 Jan; 49(1):42-8. PubMed ID: 22854066
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The role of parotid gland irradiation in the development of severe hyposalivation (xerostomia) after intensity-modulated radiation therapy for head and neck cancer: Temporal patterns, risk factors, and testing the QUANTEC guidelines.
    Owosho AA; Thor M; Oh JH; Riaz N; Tsai CJ; Rosenberg H; Varthis S; Yom SH; Huryn JM; Lee NY; Deasy JO; Estilo CL
    J Craniomaxillofac Surg; 2017 Apr; 45(4):595-600. PubMed ID: 28256385
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Preservation of oral health-related quality of life and salivary flow rates after inverse-planned intensity- modulated radiotherapy (IMRT) for head-and-neck cancer.
    Parliament MB; Scrimger RA; Anderson SG; Kurien EC; Thompson HK; Field GC; Hanson J
    Int J Radiat Oncol Biol Phys; 2004 Mar; 58(3):663-73. PubMed ID: 14967418
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Xerostomia, salivary characteristics and gland volumes following intensity-modulated radiotherapy for nasopharyngeal carcinoma: a two-year follow up.
    Sim C; Soong YL; Pang E; Lim C; Walker GD; Manton DJ; Reynolds EC; Wee J
    Aust Dent J; 2018 Jun; 63(2):217-223. PubMed ID: 29569726
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Evaluation of salivary gland function after treatment of head-and-neck tumors with intensity-modulated radiotherapy by quantitative pertechnetate scintigraphy.
    Münter MW; Karger CP; Hoffner SG; Hof H; Thilmann C; Rudat V; Nill S; Wannenmacher M; Debus J
    Int J Radiat Oncol Biol Phys; 2004 Jan; 58(1):175-84. PubMed ID: 14697436
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Importance of the initial volume of parotid glands in xerostomia for patients with head and neck cancers treated with IMRT.
    Nishimura Y; Nakamatsu K; Shibata T; Kanamori S; Koike R; Okumura M; Suzuki M
    Jpn J Clin Oncol; 2005 Jul; 35(7):375-9. PubMed ID: 15976068
    [TBL] [Abstract][Full Text] [Related]  

  • 18. 3D-conformal-intensity modulated radiotherapy with compensators for head and neck cancer: clinical results of normal tissue sparing.
    Wendt TG; Abbasi-Senger N; Salz H; Pinquart I; Koscielny S; Przetak SM; Wiezorek T
    Radiat Oncol; 2006 Jun; 1():18. PubMed ID: 16790059
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A phase II study to assess the efficacy of amifostine for submandibular/sublingual salivary sparing during the treatment of head and neck cancer with intensity modulated radiation therapy for parotid salivary sparing.
    Rosenthal DI; Chambers MS; Weber RS; Eisbruch A
    Semin Oncol; 2004 Dec; 31(6 Suppl 18):25-8. PubMed ID: 15726519
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prospective investigation and literature review of tolerance dose on salivary glands using quantitative salivary gland scintigraphy in the intensity-modulated radiotherapy era.
    Lee SW; Kang KW; Wu HG
    Head Neck; 2016 Apr; 38 Suppl 1():E1746-55. PubMed ID: 26875880
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.